• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Statements

Research Appeal

23 Oct 2006
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

On 23 October, 2006, the Chair of the Board, the Executive Director and partners of Drugs for Neglected Diseases initiative (DNDi), sent an open letter, which relates to the landmark World Health Organization (WHO) R&D Resolution 59.24, to all candidates for the WHO Director-General position.

Open Letter

Geneva, 23 October 2006

As co-promoters of the R&D Appeal launched in 2005 by Drugs for Neglected Diseases initiative and its partners, 19 Nobel Laureates and now supported by over 7500 scientists and academics worldwide, we firmly believe that governments should play a pivotal leadership role in needs-driven R&D for neglected diseases.

The landmark R&D Resolution 59.24 was approved by the member states of the World Health Assembly one week after the late WHO Director General, Dr. Lee, received the R&D Appeal in May 2006. The R&D Appeal urges global public responsibility in:

  • Setting global health R&D priorities according to patient needs
  • Establishing better strategies to stimulate essential health R&D (for diagnostics, vaccines, and drugs)
  • Providing sustained financial support to essential health R&D

We wish to remind the 13 WHO Director General candidates that the WHO, in living up to its institutional mandate, now has the imperative to play a leading role in prioritizing and creating an environment more conducive to innovative medical research that addresses the essential needs of the poor.

Found in the WHA Resolution, this spirit remains true to the main recommendations of the Report of the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) released on 3rd April 2006.

In response to a growing concern over the inadequacy of the current global system to support innovation in new medicines and essential health tools for neglected diseases, the WHA Resolution seeks to ensure that R&D efforts address the priority needs of patients living in resource-poor settings and often without access to essential medicines.
To achieve these objectives, the resolution aims to harness collaborative R&D initiatives involving governments and to ensure that progress in basic science and biomedicine is translated into improved, safe, and affordable health products – drugs, vaccines, and diagnostics.

The WHO has been given a two-year time frame in which to create a more favourable environment for needs-driven R&D. We firmly believe that, by displaying the same boldness it showed in adopting the Essential Drugs policies in the 1970s, the WHO can impose its will and influence by swiftly acting on the tenets set by the WHA Resolution.
Through philanthropic commitments made in recent years, many initiatives have been established to accelerate innovation for neglected diseases that respond to patients needs. But to ensure a long-term and sustainable response, the WHO needs to recapture its central institutional role on health and to exercise that role fully by defining needs, assessing priorities, and ensuring that other institutions and actors are held accountable in terms of their health policies and programs.

We sincerely hope the next leader of WHO will have the strength and clarity of purpose to undertake his role as director of the organization responsible for global public health.

Yves Champey                                                                    Bernard Pecoul
President of the board, DNDi                                           Executive Director, DNDi

Call to Governments

[English]

[French]


Call to governments
to provide significant and sustained support to bring essential new drugs, vaccines, and diagnostics to people suffering and dying from neglected diseases

  • Every day over 35,000 people die from infectious diseases such as AIDS, malaria, tuberculosis, and most neglected diseases such as leishmaniasis, Chagas disease and sleeping sickness.
  • These diseases affect hundreds of millions, yet we lack safe, affordable, effective, field-adapted vaccines, diagnostics, and drugs to tackle them.
  • Between 1986 and 2001, global funding for health research rose from $30 billion to US$106 billion, but progress towards new health tools for the poor remains insignificant.
  • Of 1,393 new medicines approved between 1975 and 1999, only 1% was developed for tropical diseases and tuberculosis.
  • Basic science about infectious diseases exists and biomedicine is developing extremely fast, but without political determination this progress cannot be used to develop essential products.
  • The profit-driven model of drug development is not suited to developing essential health tools for neglected diseases.
  • Current regulatory practices are poorly adapted to assessing the therapeutic advances of new drugs, vaccines and diagnostics for neglected diseases.
  • Higher levels of intellectual property protection have not resulted in increased drug R&D for global health needs.

In the last few years, this health challenge has spurred global awareness and some commitment from the international community. A number of developing countries have been strengthening their capacity for new health technologies, and their role will be increasingly critical. Not-for-profit entities have been established to accelerate innovation for neglected diseases. They are beginning to build a pipeline of projects in response to the real needs of neglected patients. These product development partnerships act as ÒvirtualÓ laboratories, working collaboratively with public research institutes, universities, and pharmaceutical and biotechnology industries. However, the majority of these entities are mainly funded by philanthropic organizations and individual donors. The response remains insufficient with only marginal involvement by wealthier governments.

There is an urgent need to correct the fatal imbalance of the current drug development model. Governments must take responsibility for global public health.

New models and financial mechanisms must be pursued. Determined policy action is needed to direct health-needs driven R&D and harness collaborative R&D initiatives. This will ensure that initial progress is translated into improved, affordable and field-adapted drugs and diagnostics that can reach patients most in need.

We urge governments to provide

  • Political leadership - Make global health and medicines a strategic sector and set R&D priorities according to the needs of patients. Only then can the world achieve the Millennium Development Goals that envision - among other things - significant progress in combating HIV/AIDS, tuberculosis, malaria and other neglected diseases.
  • Sustained financial support - Governments, rich and poor, as well as inter-governmental organisations should provide, on a sustainable basis, US$ 3 billion a year needed to reach an appropriate level of health research for diseases of the poor. To secure long-term success, funding mechanisms should be designed.
  • New rules to stimulate essential health R&D - Redirecting today's knowledge and scientific expertise to neglected needs will mean a substantial shift in the way essential health products are valued, financed and made available. A new enabling framework should include access to knowledge, chemical compounds, and research tools protected by intellectual property rights. Technology transfer and research capacity strengthening in disease-endemic countries should be at the heart of the endeavour. In addition, regulatory approval processes must be streamlined in order to rapidly deliver essential medicines to patients. The risks and benefits of each drug or vaccine must be assessed in relation to the needs of patients, the severity of the disease, and available treatments and vaccines.

Without bold, new steps, disease will continue to ravage the developing world, with global consequences. Governments should act NOW.

Initial Signatories

Appeal Partners

  • Paulo Buss (President, Oswaldo Cruz Foundation , Brazil)
  • Nirmal K. Ganguly ( Indian Council of Medical Research, India);
  • Rowan Gillies (President, Médecins Sans Frontières International);
  • Richard Jefferson (Director, BIOS Initiative , Australia);
  • Davy Koech (Director, Kenya Medical Research Institute , Kenya);
  • Philippe Kourilsky (Director General, Institut Pasteur , France);
  • Ismail Merican (Director General, Ministry of Health, Malaysia );
  • Barbara Stocking (Director, Oxfam GB)

Nobel Prize Laureates

  • Pierre-Gilles de Gennes ( Physics 1991);
  • Shirin Ebadi ( Peace 2003);
  • Adolfo Perez Esquivel ( Peace 1980);
  • Dario Fo ( Literature 1997);
  • Nadine Gordimer ( Literature 1991);
  • Roger Guillemin (Physiology or Medicine 1977);
  • José Ramos Horta ( Peace 1996);
  • Mairead Corrigan Maguire ( Peace 1976);
  • Médecins sans Frontières ( Peace 1999);
  • Rigoberta Menchú Tum ( Peace 1992);
  • Sir Paul M. Nurse (Physiology or Medicine 2001);
  • Sir John E. Sulston ( Physiology or Medicine 2002);
  • Desmond Tutu ( Peace 1984);
  • Betty Williams ( Peace 1976);
  • Jody Williams ( Peace 1997)
  • Gunter Grass (Literature 1999)
  • Stanley B. Prusiner  (Physiology or Medicine 1997)
  • Prof. Rolf.M. Zinkernagel (Physiology or Medicine 1996)

Scientists and Physicians

  • Kirana Bhatt (Department of Medicine, University of Nairobi, Kenya);
  • Leigh Bissett (British Medical Association, UK);
  • Pierre-Etienne Bost (Deputy Director, Institut Pasteur, France);
  • Yves Champey (Chair, DNDi Board of Directors, France);
  • Simon Croft (R&D Director, DNDi, Switzerland);
  • Alan Fenwick OBE (Chair of Tropical Parasitology and Director Schistosomiasis Control Initiative, Imperial College     London, UK);
  • Peter Folb (Medical Research Council, South Africa);
  • Silvio Garattini (Director, The Mario Negri Institute of Pharmacological Research, Italy);
  • Lalit Kant (Deputy Director General, Indian Council of Medical Research, India);
  • Helen Lee (Chief of the Diagnostic Development Unit, University of Cambridge, UK);
  • Stephen Maurer (Goldman School of Public Policy, Berkeley University, USA – Tropical Disease Initiative);
  • Carlos Morel ( Scientific Coordinator , Oswaldo Cruz Foundation, Brazil);
  • Visweswaran Navaratnam (Clinical Pharmacologist, University of Science, Malaysia);
  • James Orbinski (Munk Centre for International Studies, University of Toronto, Canada);
  • Bernard Pécoul (Executive Director, DNDi, Switzerland);
  • Bennett Shapiro (former EVP and Head of Research, Merck & Company, USA);
  • Richard Smith (Board member, Public Library of Science and former editor BMJ, USA);
  • C. P. Thakur (Former Union Minister, Ministry of Health and Family, India);
  • Julio Urbina (IVIC - Venezuelan Institute for Scientific Research, Venezuela);
  • Nick White (The Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme, Thailand);
  • Dyann Wirth (Harvard School of Public Health, USA) ;
  • Yongyuth Yuthavong (Senior Researcher, NSTDA-National Science & Technology Development Agency, Thailand)
  • Nubia Boechat (Director of far Manguinhos, Brazil)
  • Paul L Herrling (Head of Corporate Research, Novartis)

Others

  • Giovanni Berlinguer (Member of the European Parliament –MEP-, Committee on Public Health);
  • John Bowis (MEP, Rapporteur on neglected diseases);
  • Dorette Corbey (MEP));
  • Eduardo Galeano ( Uruguayan journalist, essayist and writer);
  • Thomas Gebauer (Executive Director, Medico International);
  • Paul Hunt (UN Special Rapporteur on the Right to the highest attainable standard of health );
  • Glenys Kinnock (MEP);
  • Stephen Lewis (UN Secretary General's Special Envoy for HIV/AIDS in Africa );
  • Ney Matogrosso ( Brazilian singer and songwriter);
  • Luisa Morgantini (MEP, President of the Development Committee);
  • Mary Robinson (former President of Ireland, former High Commissioner for Human Rights – Executive Director, The Ethical Globalisation Initiative ) ;
  • Viviane Senna (President, Ayrton Senna Institute),
  • Susannah Sirkin (Deputy Director, Physicians for Human Rights);
  • Ismael Serageldin (President MURS International);
  • Carl Schlyter (MEP, Co-chair of the Economic Committee of ACP-EU Parliamentary Assembly);
  • Walter Veltroni (Mayor of Rome and 2004 World Mayors finalist for Europe)

Partner Organisations

DNDi in association with:

  • Davy Koech, Director, Kenya Medical Research Institute, Kenya
  • Paolo Buss, President, Oswaldo Cruz Foundation, Brazil
  • Philippe Kourilsky, Director General, Institut Pasteur, France
  • Ismail Merican, Director General, Ministry of Health, Malaysia
  • Nirmal K. Ganguly, Director General, Indian Council of Medical Research, India
  • Rowan Gillies, President Médecins Sans Frontières International
  • Barbara Stocking, Director, Oxfam GB
  • Richard Jefferson, Director BIOS Initiative, Australia

CIPIH Report

Created in May 2003 at the 56th World Health Assembly, the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) aims to review the interfaces and linkages between intellectual property rights, innovation and public health in the light of current evidence and examine in depth how to stimulate the creation of new medicines and other products for diseases that mainly affect developing countries.

CIPIH website

CIPIH report 

Policy advocacy

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

VIEW ALL

Speak out

Please help us raise awareness by sharing this story.

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo